Navigation Links
Increased SVR and Decreased Adverse Events Reported in Final Results of Phase 3 Study on Telaprevir
Date:11/1/2010

vents leading to treatment discontinuation occurred in 7 percent of patients in the arm receiving telaprevir combination treatment for 12 weeks, 8 percent in telaprevir for 8 weeks, and 4 percent in the peginterferon alfa-2a and ribavirin arm.

Abstract title:

Telaprevir in Combination with Peginterferon and Ribavirin in Genotype 1 HCV Treatment-Naive Patients: Final Results of Phase 3 ADVANCE Study

About the AASLD

AASLD is the leading medical organization for advancing the science and practice of hepatology. Founded by physicians in 1950, AASLD's vision is to prevent and cure liver diseases. This year's Liver Meeting®, held in Boston, Massachusetts, October 29-November 2, will bring together more than 7,500 researchers from 55 countries.

A pressroom will be available from October 30 at the annual meeting. For copies of abstracts and press releases, or to arrange for pre-conference research interviews contact Gregory Bologna at 703-299-9766. To pre-register, call Ann Haran at 703-299-9766.

Press releases and all abstracts are available online at www.aasld.org.

Quote from Dr. Jacobson: "This phase 3 trial confirms previous findings that telaprevir confers  higher rates of viral cure in patients with the highly prevalent genotype 1 when compared with the current standard of care, with the added advantage of a  shorter total duration of treatment  in the majority of patients.  Although rash and anemia were more common with telaprevir, treatment discontinuation due to side effects was very infrequent and side effects attributable to the drug are reversible.  This study, along with others on protease inhibitors at this year's meeting, heralds an  exciting new era in HCV therapy in which increasing numbers of patients will be cured and spared the life-threatening risks of advanced liver disease."Media Contact: Gregory Bologna703/299-9766gbologna@aasld.o
'/>"/>

SOURCE American Association for the Study of Liver Diseases (AASLD)
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Nonprescription Drugs Cost Structures Fluctuate with Increased Cost of Goods, According to Kline
2. FDA: Possible Increased Risk of Thigh Bone Fracture With Bisphosphonates
3. Introduction of New Products and Increased Uptake of Innovative Materials to Drive US Bone Graft Substitute Market to Nearly $2.3 Billion by 2015
4. Alere Inc. Announces Pricing of Senior Subordinated Notes Offering; Offering Size Increased to $400.0 Million
5. Max Neeman International Expands Upon Cardiology and Device Trial Experience to Meet Increased Medical Device Development in India
6. Through 2019, Increased Generic Erosion of Key Agents Such as Lamictal and Depakote/Depakote ER Will Cause a Precipitous $2.3 Billion Decline in the Bipolar Disorder Drug Market
7. Biostar Pharmaceuticals, Inc. Second Quarter Revenue Increased 46.4% to $19.4 Million
8. Medical Affairs Budget & Staffing Remain Top Challenges Despite Increased Funding
9. HealthWarehouse.com Now Offers Over 1,000 Medications Under $25 Bringing Increased Affordability to Consumers
10. APC Group, Inc. Reports Fiscal Year End Sales Revenues Increased 30% for 2009
11. New Study Links dLife to Increased Rx Drug Usage Among Diabetes Consumers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Calif. , Sept. 17, 2014  Neuraltus Pharmaceuticals, ... Company,s Phase 2 clinical program of NP001 for the ... Gehrig,s disease) are being highlighted today in an ... ALS Research Group , being held in ... a  post hoc  analysis, administration of a high dose ...
(Date:9/17/2014)... 2014  Fortune Oil and Gas, Inc. (OTCPink:FOGC), today ... Manzo Pharmaceuticals, Inc. with the symbol (OTCPink : FOGCD). ... 17, 2014. Also taking effect today is a ten ... a pivotal event in the company,s progress according to ... could not proceed with the plan and still have ...
(Date:9/17/2014)... Pa. , Sept. 17, 2014  Auxilium Pharmaceuticals, ... company, today confirmed that Auxilium has received an unsolicited, ... ENDP ) to acquire all of the outstanding shares ... per share in cash and Endo stock, subject to ... the unsolicited, non-binding proposal that Auxilium received from Endo ...
Breaking Medicine Technology:Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 3Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 2Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 3Auxilium Responds To Unsolicited Proposal From Endo International 2Auxilium Responds To Unsolicited Proposal From Endo International 3Auxilium Responds To Unsolicited Proposal From Endo International 4Auxilium Responds To Unsolicited Proposal From Endo International 5Auxilium Responds To Unsolicited Proposal From Endo International 6Auxilium Responds To Unsolicited Proposal From Endo International 7
... CHICAGO, June 9, 2011 Today a Cook County jury ... Chicago area man, Steven Johansen, who was administered Baxter blood ...  This was the first of hundreds of pending lawsuits on ... are pending in the Circuit Court of Cook County in ...
... Inc. today announced an agreement with the U.S. Department of ... the marketing and promotion of Keppra®, an anti-epileptic prescription medicine. ... this investigation occurred more than six years ago, and as ... United States since learning of the investigation in 2008. ...
Cached Medicine Technology:Nolan Law Group: Jury Finds Against Baxter Healthcare In Nation's First Contaminated Chinese Heparin Case 2UCB, Inc. Resolves Investigation of Past Keppra® Marketing and Promotional Activities 2
(Date:9/17/2014)... 17, 2014 The International Journal of Surgery ... its archive of previously published content: after 24 months published ... aim of the IJS is to improve surgical ... making these articles available to all will improve efforts to ... IJS said, "The journal has always been a great ...
(Date:9/17/2014)... In ongoing coverage of formulary exclusion ... (DBN) continues to find criticism surrounding the tactic. ... issue , CVS Caremark Corp. and Express Scripts ... cut more drugs than ever, but industry consultants ... likely to achieve. Despite finding the strategy problematic, ...
(Date:9/17/2014)... New York, N.Y. (PRWEB) September 17, 2014 ... for fans taking part in the fitness industry’s most ... in Las Vegas, NV. Two fans will each take ... fully loaded with Neon Sport supplements and gear. Fitmark ... booth during the Olympia Expo, September 19-20th. , ...
(Date:9/17/2014)... Mission Viejo, CA (PRWEB) September 17, 2014 ... meetings and events, announced today it has released ... engagement at large meetings and corporate events. The ... up, enhance presentation and document management capabilities and ... speaker and participants. , Lintelus Meeting 3.1 ...
(Date:9/17/2014)... 2014 Market Research Report on ... in-depth research report on the China DEHP Plasticizer ... including its definition, classification, application, and industry chain ... covers the international market analysis, including China’s domestic ... macroeconomic environment & economic situation analysis. The report ...
Breaking Medicine News(10 mins):Health News:AIS Newsletter Continues to Find Industry Criticism of PBM Formulary Exclusion Lists 2Health News:AIS Newsletter Continues to Find Industry Criticism of PBM Formulary Exclusion Lists 3Health News:Electrifying Sports Nutrition Brand, Neon Sport, Pairs with Global Fitness Bag & Luggage Brand, Fitmark Bags, for an Exclusive Giveaway at Olympia Expo, This Weekend 2Health News:Lintelus Energizes Audiences with the Latest Version Of its Multi-Screen Interactive Software 2Health News:DEHP Plasticizer Industry & SiC Substrates Market Analysis For (NA, Asia, Europe & ROW) Research Now at DeepResearchReports.com 2Health News:DEHP Plasticizer Industry & SiC Substrates Market Analysis For (NA, Asia, Europe & ROW) Research Now at DeepResearchReports.com 3
... 2012) According to the results of a new ... Journal of the American College of Surgeons , ... disease and were not meaningfully involved in treatment discussions ... As a result, the study,s investigators determined that there ...
... News) -- A drug commonly used to treat patients with ... older than 40 years who have Down syndrome and Alzheimer,s, ... animal studies of the Alzheimer,s drug, memantine, showed promising results ... with Down syndrome aged 40 and older revealed the opposite, ...
... January/February issue of Annals takes an up-close look ... a single individual, a phenomenon that is growing at an ... is estimated by the year 2020, 25 percent of the ... costs for managing these conditions will reach $1.07 trillion. In ...
... injury (AKI) has severe consequences, with a 25 to 80 ... to diagnose AKI using a urine test, enabling emergency departments ... the hospital. The study will be published online on January ... of Cardiology. Physicians typically measure a patient,s creatinine ...
... Steven Reinberg HealthDay Reporter , MONDAY, Jan. 9 ... heartbreaking grief, suggests new research that finds losing a loved ... a day of a significant other,s death, heart attack risk ... at data on nearly 2,000 heart attack patients. And within ...
... risk of suffering a heart attack increases by approximately 21 ... one, according to a study lead by researchers at Beth ... 9 online in the journal Circulation found the ... the first week after the death of a loved one, ...
Cached Medicine News:Health News:Early-stage breast cancer patients lack knowledge; may not receive treatment they prefer 2Health News:Early-stage breast cancer patients lack knowledge; may not receive treatment they prefer 3Health News:Alzheimer's Med Seems Ineffective in Those With Down Syndrome 2Health News:January/February 2012 Annals of Family Medicine 2Health News:January/February 2012 Annals of Family Medicine 3Health News:January/February 2012 Annals of Family Medicine 4Health News:January/February 2012 Annals of Family Medicine 5Health News:January/February 2012 Annals of Family Medicine 6Health News:January/February 2012 Annals of Family Medicine 7Health News:January/February 2012 Annals of Family Medicine 8Health News:January/February 2012 Annals of Family Medicine 9Health News:Biomarkers identify acute kidney injury in emergency patients 2Health News:Grief Is a Real Heartbreaker, Study Finds 2Health News:Grief Is a Real Heartbreaker, Study Finds 3Health News:Heart attack risk rises after loss of loved one 2
... QFill2 is the ideal system for fast, accurate ... pressure driven, pinch valve controlled dispensing mechanism, ensures ... all of the components that come into contact ... clean, and autoclave. The unique compact design saves ...
... system for fast, accurate filling of 96 or ... controlled dispensing mechanism, ensures that no liquid can ... that come into contact with the liquid path ... unique compact design saves valuable bench space and ...
... Personal Pipettor is a cost-effective ... pipetting needs, from reagent additions ... more. Systems are available in ... using either fixed or disposable ...
... the newest addition to Thermos Multidrop family. ... of 1-50 l into 384- and 96-well ... a 384-well plate takes only 14 s. ... accuracy typically 10% at 2 l, which ...
Medicine Products: